Physician profile
Amy Cohen
NPI 1215093935
$3,921.96
in general payments reported to CMS, 2019-2025
14 companies · $529 in 2025
The $529 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $331 · 2022: $1,216 · 2023: $1,046 · 2024: $800 · 2025: $529.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,290 · Education: $84.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,290.37 |
| Education | $84.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,290.37 | 2021-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $547.27 | 2022-2025 | Caplyta |
| Alkermes, INC. | $513.98 | 2021-2023 | Vivitrol, Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $402.36 | 2021-2025 | Qelbree |
| Indivior INC. | $239.14 | 2021-2024 | Sublocade |
| Lundbeck LLC | $212.98 | 2022-2024 | Rexulti |
| Janssen Pharmaceuticals, INC | $171.63 | 2022-2023 | Invega Sustenna |
| Neurocrine Biosciences, INC. | $130.39 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $123.25 | 2023 | Uzedy |
| Tris Pharma INC | $104.52 | 2022 | |
| Neos Therapeutics, LP | $66.47 | 2021-2022 | |
| Abbvie INC. | $51.63 | 2021 | |
| Ironshore Pharmaceuticals INC. | $35.81 | 2021-2023 | Jornay Pm |
| Neurelis, INC. | $32.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.